WuXi Biologics Recognized by CDP for Climate Change Leadership for Second Consecutive Year
SHANGHAI, April 22, 2025 /PRNewswire/ -- WuXi Biologics ('WuXi Bio') (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced it has been recognized by CDP, the world's foremost environmental non-profit reporting organization, for its leadership in disclosure transparency and performance excellence in the area of climate change. This marks the second consecutive year the company has achieved this honor.
CDP is recognized as the global standard for corporate environmental reporting, and its annually published ratings are widely used to drive investment and procurement decisions toward a net-zero, sustainable and resilient economy. Companies are evaluated on their awareness of environmental issues, management methods and advancements in environmental stewardship. In 2024, nearly 25,000 companies — representing two-thirds of the global market value — reported their environmental data through CDP. WuXi Biologics stood out among these companies with an 'A-" score for leadership on climate change.
Committed to the Science Based Target initiative (SBTi), WuXi Biologics has adopted an integrated strategy to tackle climate change issues, with measurable targets and a refined roadmap. The Company aims to achieve net-zero emissions from overall operations by 2050, and in 2024, it realized a 30% GHG (Scope 1 and Scope 2) emission intensity reduction from the base year 2020. The company also actively pursues opportunities to decrease energy consumption, advocating energy-saving initiatives from process optimization, equipment upgrade, and infrastructure replacement and renovation. The company actively deploys rooftop photovoltaic power projects, and has achieved a 100% renewable electricity supply at its Ireland site.
Dr. Chris Chen, CEO of WuXi Biologics and Chairman of its ESG Committee, commented, 'We are very pleased to be recognized once again by CDP for climate change leadership, an acknowledgement that further inspires our steadfast dedication to enhancing our sustainability performance. It is fitting that we are making this announcement on Earth Day as we, along with organizations and communities around the world, put special focus on the importance of long-term ecological sustainability. As a global leader in Green CRDMO, we consistently deliver ESG excellence, enable partners worldwide with end-to-end solutions to fulfil their ESG commitments, and work together with all of our stakeholders to promote responsible practices throughout the entire value chain.'
As a participant of the United Nations Global Compact (UNGC) and the Pharmaceutical Supply Chain Initiative (PSCI), WuXi Biologics proactively advocates sustainability, and has earned widespread recognition for its efforts. It was granted an MSCI AAA Rating; awarded an EcoVadis Platinum Medal; listed in the Dow Jones Sustainability Indices (DJSI) for two consecutive years; included in the UNGC 20 Case Examples of Sustainable Development for 20 Years Collection for its world-leading green biologics solutions; recognized as a Sustainalytics industry and regional ESG top-rated company for five consecutive years; merited an 'A' CDP Water Security score; selected as a Constituent of the FTSE4Good Index Series; listed in the Hang Seng ESG 50 Index; and rated as Prime by ISS ESG Corporate Rating.
About CDP
CDP is a global non-profit that runs the world's only independent environmental disclosure system. As the founder of environmental reporting, the organization believes in transparency and the power of data to drive change. Partnering with leaders in enterprise, capital, policy and science, CDP surfaces the information needed to enable Earth-positive decisions. It helped more than 24,800 companies and 1,100 cities, states and regions disclose their environmental impacts in 2024. Financial institutions with more than a quarter of the world's institutional assets use CDP data to help inform investment and lending decisions. Aligned with the ISSB's climate standard, IFRS S2, as its foundational baseline, CDP integrates best-practice reporting standards and frameworks in one place. The team is truly global, united by a shared desire to build a world where people, planet and profit are truly balanced.
About WuXi Biologics
WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.
With over 12,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of December 31, 2024, WuXi Biologics is supporting 817 integrated client projects, including 21 in commercial manufacturing (excluding COVID CMO projects).
WuXi Biologics regards sustainability as the cornerstone of long-term business growth. The company continuously drives green technology innovations to offer advanced end-to-end Green CRDMO solutions for its global partners while consistently achieving excellence in Environment, Social and Governance (ESG). Committed to creating shared value, it collaborates with all stakeholders to foster positive social and environmental impacts and promote responsible practices that empower the entire value chain.
For more information about WuXi Biologics, please visit: www.wuxibiologics.com.
View original content: https://www.prnewswire.com/news-releases/wuxi-biologics-recognized-by-cdp-for-climate-change-leadership-for-second-consecutive-year-302434077.html
SOURCE WuXi Biologics
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
30 minutes ago
- Yahoo
British Business Bank invests $13m in Shawbrook
The British Business Bank has announced a £10m ($13.3m) investment in Shawbrook Bank's £75m Tier 2 note issuance. According to the UK Government's economic development bank, its investment follows a previous £30m subscription to Shawbrook's Tier 2 note issuance in 2020. The lender's Tier 2 capital note investments are designed to support recipient banks in expanding their services, thereby increasing the supply of finance to smaller businesses in the UK. With the capital raised through this issuance, Shawbrook will continue supporting growth in its specialist small business markets. British Business Bank managing director of direct financial institution solutions Richard Bowen said: 'This £10m investment is our third Tier 2 investment in Shawbrook Bank and follows a £150m ENABLE Build transaction in 2024, extending a successful partnership since our first investment in 2015. 'I am delighted to continue our work together to support diversity within the small business finance markets, helping fuel the growth of smaller businesses across the UK.' Shawbrook Bank CFO Dylan Minto added: 'We are pleased to have successfully completed the issuance of £75m Tier 2 capital, strengthening our capital base to support our growth and strategic ambitions. 'We value the continued support from British Business Bank, with their long-term participation serving as a strong endorsement of our strategy and providing the capital foundation to further grow our SME lending, supporting businesses across the UK.' Last month, Shawbrook extended a £20m revolving credit facility to ScotLend, marking its first transaction with a Scottish-based lender. This facility aims to enhance ScotLend's presence in the bridging finance market across the UK. In the full year 2024, Shawbrook's loan book grew by 16% to £15.2bn, driven by strong demand in specialist commercial and retail markets. However, underlying profit before tax decreased to £294m from £302m in 2023. "British Business Bank invests $13m in Shawbrook" was originally created and published by Leasing Life, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. 擷取數據時發生錯誤 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤
Yahoo
31 minutes ago
- Yahoo
New Treatment May Cure Severe Type 1 Diabetes, Study Finds
A dozen volunteers with severe type 1 diabetes showed clear improvements in their condition 12 months after receiving a revolutionary stem cell treatment, with all but two dropping their insulin therapy altogether. The phase 1/phase 2 clinical trial results provide hope for the 8.4 million people around the world with type 1 diabetes; an autoimmune condition where the immune system damages insulin-producing cells. While more extensive studies are required to see how long the benefits of the treatment can last, the new therapy developed by Boston-based Vertex Pharmaceuticals provides strong evidence that it's possible to replace the body's lost insulin production using infusions of stem cells. Related: People with type 1 diabetes are dependent on a precarious balance of insulin therapy for their whole lives. If their insulin drops too low, cells are unable to make use of the sugar in their bloodstream, leading to a buildup that can damage organs. If insulin is too high, patients are plunged into hypoglycemia, which can result in a loss of consciousness, seizures, coma, or death. The pancreas's islet cells are responsible for maintaining most of our bodies' insulin levels. Donor transplants of healthy versions of these cells have shown promise in treating type 1 diabetes in the past, but multiple donors are required, and donors are rare. So University of Toronto surgeon Trevor Reichman and colleagues infused 12 patients with islet cells derived from human stem cells in a treatment known as zimislecel. The patients also received immunosuppressive treatment before and after their zimislecel infusion. The islets not only produced insulin inside their bodies, but they did so at safe levels, reducing the patients' dependence on costly doses of insulin. "These findings showed that zimislecel islet cells were functional and self-regulated appropriately," the researchers write in their paper. The mild to moderate side-effects, including decreased kidney function and the anticipated drop in immune cells, were all linked with the immunosuppressive therapy. Sadly, two additional participants died during the trial; one from an infection arising from surgery and the other from complications due to an unrelated condition. As there were no serious adverse events attributed to the new islet cell therapy, the clinical trials are have progressed into phase 3. "These findings provide evidence that pancreatic islets can be effectively produced from pluripotent stem cells and used to treat type 1 diabetes," Reichman and team conclude. This research was published in NEJM. Scientists Identify New Blood Group, And It's The World's Rarest Extreme Heat Wave Scorches The US: Here's How You Can Stay Safe Your Brain Has a Hidden Rhythm, And It May Reveal How Smart You Are
Yahoo
38 minutes ago
- Yahoo
Is Snap-on Stock Underperforming the Nasdaq?
Kenosha, Wisconsin-based Snap-on Incorporated (SNA) manufactures and markets tools, equipment, diagnostics, and repair information and systems solutions for professional users. Valued at a market cap of $16 billion, the company serves the aviation and aerospace, natural resources, agriculture, infrastructure construction, government and military, mining, power generation, and technical education industries. Companies worth $10 billion or more are typically classified as 'large-cap stocks,' and SNA fits the label perfectly, with its market cap exceeding this threshold, underscoring its size, influence, and dominance within the tools & accessories industry. The company is a powerhouse in professional-grade tools and equipment, renowned for its unmatched quality, innovation, and direct-to-user sales model. It sustains a premium brand reputation through rigorous innovation and robust IP, backed by over 4,000 patents and substantial R&D investments. Robotaxis, Powell and Other Key Things to Watch this Week The 7 Signs Your Stock Is A Buyout Target Looking to Gamble on Hard-Hit Solar Stocks? This Is the Top-Rated Ticker Now. Stop Missing Market Moves: Get the FREE Barchart Brief – your midday dose of stock movers, trending sectors, and actionable trade ideas, delivered right to your inbox. Sign Up Now! This tools and equipment manufacturer has slipped 18.2% from its 52-week high of $373.90, reached on Nov. 27, 2024. Shares of SNA have declined 7.3% over the past three months, lagging behind the Nasdaq Composite's ($NASX) 9.9% return during the same time frame. Moreover, on a YTD basis, shares of SNA are down 9.9%, compared to NASX's marginal gain. However, in the longer term, SNA has soared 13.8% over the past 52 weeks, outperforming NASX's 9.7% rise over the same time frame. To confirm its bearish trend, SNA has been trading below its 200-day moving average since mid-April, with minor fluctuations, and has remained below its 50-day moving average since mid-December, 2024, with slight fluctuations. On Apr. 17, shares of Snap-on plunged 8% after its weaker-than expected Q1 earnings release. The company's revenue declined 3.5% year-over-year to $1.1 billion and fell short of the consensus estimates by 5%. Moreover, its EPS of $4.51 fell 8.1% from the year-ago quarter and missed the forecasted figure by 6.2%. The disappointing performance was primarily driven by weaker results in its commercial & industrial group and tools group, with both segments reporting declines in organic sales and operating earnings. Snap-on has outperformed its rival, Stanley Black & Decker, Inc.'s (SWK) 23.2% drop over the past 52 weeks and 19.6% fall on a YTD basis. Despite SNA's recent underperformance, analysts remain moderately optimistic about its prospects. The stock has a consensus rating of "Moderate Buy' from the 10 analysts covering it, and the mean price target of $345 suggests a 12.8% premium to its current price levels. On the date of publication, Neharika Jain did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on
